You are here: Industry Insights > United Therapeutics

News List

United Therapeutics Receives Orphan Drug Designation for Treprostinil for Idiopathic Pulmonary Fibrosis americanpharmaceuticalreview
December 30, 2020
United Therapeutics announced the United States Food and Drug Administration (FDA) has granted orphan drug designation to treprostinil for the treatment of patients with idiopathic pulmonary fibrosis (IPF).
United Therapeutics teamed with pumpmaker to block Remodulin generics, Sandoz suit says fiercepharma
April 21, 2019
It took Novartis' Sandoz years to reach the market with a generic to United Therapeutics’ pulmonary arterial hypertension drug Remodulin, but last month, the company managed to do just that.
United Therapeutics scraps development of esuberaprost after late-stage study failure in PAH firstwordpharma
April 09, 2019
United Therapeutics on Monday announced that it will end development of esuberaprost for the treatment of pulmonary ……
As Remodulin copies roll, United Therapeutics faces big hit to its top seller fiercepharma
March 29, 2019
United Therapeutics has been bracing for copycat competition to its big moneymaker Remodulin, and now it's here.
MannKind and United Therapeutics to advance dry powder treprostinil pharmaceutical-technology
September 06, 2018
US-based biopharmaceutical company MannKind has entered an exclusive licensing and collaboration agreement with United Therapeutics over a dry powder formulation of treprostinil.